Investigators from CMR Curediab Metabolic Research GmbH recently disclosed preclinical data for a novel hepatoprotective thioacrylamide compound, HK-3, being developed for the treatment of metabolic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results